Brent Binkowski

Executive

Vascular Solutions IncCVRx, Inc.

Insider activity · 24 months1 buy1 saleCumulative net flow

Nov 24 · 0 buys · 0 salesDec 24 · 0 buys · 0 salesJan 25 · 0 buys · 0 salesFeb 25 · 0 buys · 0 salesMar 25 · 0 buys · 0 salesApr 25 · 0 buys · 0 salesMay 25 · 0 buys · 0 salesJun 25 · 0 buys · 0 salesJul 25 · 0 buys · 0 salesAug 25 · 0 buys · 0 salesSept 25 · 0 buys · 0 salesOct 25 · 0 buys · 0 salesNov 25 · 0 buys · 0 salesDec 25 · 0 buys · 0 salesJan 26 · 0 buys · 0 salesFeb 26 · 0 buys · 0 salesMar 26 · 0 buys · 0 salesApr 26 · 0 buys · 0 salesMay 26 · 0 buys · 0 salesJun 26 · 0 buys · 0 salesJul 26 · 0 buys · 0 salesAug 26 · 1 buy · 1 saleSept 26 · 0 buys · 0 salesOct 26 · 0 buys · 0 sales

Total declarations

Companies

▲ Purchases (1 ops.)

€66k

▼ Sales (1 ops.)

€2,892

Latest filing published 13 Aug 2026 for CVRx, Inc., €2,892.

Filing timeline

BuySale

Brent Binkowski

Insider track record

Disclosed buys

Disclosed sells

Not enough buy signals with a settled T+90 horizon to measure a track record yet.

Signal history

No signal scores available.

Brent Binkowski: trading record in brief

Filings by Brent Binkowski span 2 companies, the busiest being CVRx, Inc. and Vascular Solutions Inc. Over a trading history stretching from 22 January 2016 to 13 August 2026, the count stands at 6 filings.

Market trades split into 1 purchase (€66k) and 1 sale (€2,892). On balance, insiders were net buyers of €63k. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. The rest of the record consists of 3 share grants. Since January 2026: 1 purchase and 1 sale on the market.

Most recently, on 13 August 2026, the filings show an open-market sale worth €2,892 in CVRx, Inc. The last purchase on record was published on 13 August 2026, which is 71 days ago. The median gap between a trade and its publication by SEC (Form 4) is 4 days. US insiders must file a Form 4 within two business days of a trade. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.